London · Delayed Price · Currency is GBP · Price in GBX AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of GBP 223.03 billion. The enterprise value is 240.89 billion.
| Market Cap | 223.03B |
| Enterprise Value | 240.89B |
Important Dates
The next confirmed earnings date is Wednesday, April 29, 2026.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | Feb 19, 2026 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has decreased by -0.06% in one year.
| Current Share Class | 1.55B |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 66.99% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 29.59 and the forward PE ratio is 18.42. AstraZeneca's PEG ratio is 1.43.
| PE Ratio | 29.59 |
| Forward PE | 18.42 |
| PS Ratio | 5.11 |
| PB Ratio | 6.16 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 25.51 |
| P/OCF Ratio | 20.60 |
| PEG Ratio | 1.43 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.48, with an EV/FCF ratio of 27.56.
| EV / Earnings | 31.71 |
| EV / Sales | 5.52 |
| EV / EBITDA | 16.48 |
| EV / EBIT | 22.70 |
| EV / FCF | 27.56 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.61.
| Current Ratio | 0.94 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 1.51 |
| Debt / FCF | 2.52 |
| Interest Coverage | 10.47 |
Financial Efficiency
Return on equity (ROE) is 22.84% and return on invested capital (ROIC) is 16.48%.
| Return on Equity (ROE) | 22.84% |
| Return on Assets (ROA) | 8.19% |
| Return on Invested Capital (ROIC) | 16.48% |
| Return on Capital Employed (ROCE) | 17.12% |
| Weighted Average Cost of Capital (WACC) | 5.38% |
| Revenue Per Employee | 454,142 |
| Profits Per Employee | 79,055 |
| Employee Count | 96,100 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, AstraZeneca has paid 1.61 billion in taxes.
| Income Tax | 1.61B |
| Effective Tax Rate | 17.49% |
Stock Price Statistics
The stock price has increased by +23.43% in the last 52 weeks. The beta is 0.23, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +23.43% |
| 50-Day Moving Average | 14,390.04 |
| 200-Day Moving Average | 12,589.63 |
| Relative Strength Index (RSI) | 43.60 |
| Average Volume (20 Days) | 1,950,583 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of GBP 43.64 billion and earned 7.60 billion in profits. Earnings per share was 4.86.
| Revenue | 43.64B |
| Gross Profit | 35.66B |
| Operating Income | 10.62B |
| Pretax Income | 9.21B |
| Net Income | 7.60B |
| EBITDA | 14.33B |
| EBIT | 10.62B |
| Earnings Per Share (EPS) | 4.86 |
Balance Sheet
The company has 4.25 billion in cash and 22.07 billion in debt, with a net cash position of -17.82 billion or -11.49 per share.
| Cash & Cash Equivalents | 4.25B |
| Total Debt | 22.07B |
| Net Cash | -17.82B |
| Net Cash Per Share | -11.49 |
| Equity (Book Value) | 36.20B |
| Book Value Per Share | 23.32 |
| Working Capital | -1.41B |
Cash Flow
In the last 12 months, operating cash flow was 10.83 billion and capital expenditures -2.09 billion, giving a free cash flow of 8.74 billion.
| Operating Cash Flow | 10.83B |
| Capital Expenditures | -2.09B |
| Free Cash Flow | 8.74B |
| FCF Per Share | 5.64 |
Margins
Gross margin is 81.71%, with operating and profit margins of 24.33% and 17.41%.
| Gross Margin | 81.71% |
| Operating Margin | 24.33% |
| Pretax Margin | 21.11% |
| Profit Margin | 17.41% |
| EBITDA Margin | 32.82% |
| EBIT Margin | 24.33% |
| FCF Margin | 20.03% |
Dividends & Yields
This stock pays an annual dividend of 2.36, which amounts to a dividend yield of 1.64%.
| Dividend Per Share | 2.36 |
| Dividend Yield | 1.64% |
| Dividend Growth (YoY) | -3.83% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 47.39% |
| Buyback Yield | 0.06% |
| Shareholder Yield | 1.71% |
| Earnings Yield | 3.41% |
| FCF Yield | 3.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.24 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.24 |
| Piotroski F-Score | 7 |